Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
HubSpot drew a fresh analyst downgrade Monday just as its cost to borrow climbed sharply, adding two more signals to a stock already carrying 6.2% short interest as a percentage of free float.
Why this matters: Raymond James cut HubSpot from Outperform to Market Perform on 5 October, removing a bull-side voice at a moment when the stock has fallen roughly 11% over the past month. The downgrade landed alongside a 62.5% weekly jump in cost to borrow, to 0.41%. Neither signal is extreme in isolation, but their simultaneous arrival sharpens the debate around a stock with a next earnings print in less than 30 days.
The Raymond James move by Brian Peterson stands out because it runs against the grain of post-earnings analyst activity from mid-September. After the Q3 print, BMO Capital raised its target to $250, Truist lifted to $275, and UBS moved to $290. All three maintained their ratings. RBC held its Outperform with a $300 target. Needham did the same.
The consensus sits at "hold" with a mean price target of $249.71, against a close of $220.61 on 5 October. That implies roughly 13% upside from current levels.
The bull case centres on HubSpot's unified platform, an AI layer called Aviator, and a 4,000-plus partner network that management says lifts net revenue retention in upmarket deals. The bear case points to tepid SMB demand, macro pressure on buying decisions, and a valuation that leaves little room if revenue growth slows from above 20%.
The 62.5% weekly rise in cost to borrow sounds dramatic. The absolute level of 0.41% is still low. More telling is the direction: CTB has risen 36% over the past month as well. Shares short stand at roughly 3.26 million, 6.2% of free float, down about 5% on the day and nearly 11% over the past month.
Availability remains extremely wide at 3,900%, meaning roughly 39 shares sit available to borrow for every one already lent out. The lending market is not tight. The CTB move is worth watching, but it does not yet suggest a crowded short or a borrow squeeze.
The put-to-call ratio of 1.19 sits slightly above its 20-day mean of 1.14, a z-score of 0.76. Options positioning is mildly defensive but not alarmed. The ORTEX short score is 39.8, little changed over the past week.
On the institutional side, BlackRock filed an updated 13G on 5 October disclosing a 10.4% stake, up from 6.4% previously. T. Rowe Price holds 8.76% as of July. AQR added 803,652 shares as of end-June. These are passive and quantitative holders, but the BlackRock amendment is fresh.
Insider activity over the past 90 days is net negative at roughly $5.8 million, mostly tax-withholding transactions coded "F" alongside one discretionary sale by director Brian Halligan of 8,500 shares on 15 September under a pre-arranged 10b5-1 plan.
Next earnings are scheduled for 4 November, 29 days away.
See the live data behind this article on ORTEX.
Open HUBS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
